p53基因突变和p16基因缺失与肝癌的相关性

目的:检测肝癌患者血浆中p53基因突变和细胞核中p16基因缺失的机率,研究与疾病发生、发展的相关性并探讨其意义.方法:实验采用聚合酶联链式反应(PCR)扩增p53基因外显子5～8和免疫组织化学方法SP-p16,对其突变和缺失进行分析.结合临床患者有无肝组织以外转移来对比差异性.结果:33例肝癌患者中,有17例结果显示血浆循环核酸p53基因突变;有转移病灶组18例的突变率高于无转移病灶组15例.结论:血浆p53基因突变和p16基因缺失与肝癌的发生、与疾病的轻重及病灶转移有相关性,突变机率在临床鉴别诊断和治疗预后中有参考价值.

Correlation of p53 gene mutation and p16 gene deletion with hepatocellular carcinoma

AIM: To detect the probability of p53 gene mutation and p16 gene deletion in the plasma of the patients with hepatocellular carcinoma (HCC) and to explore its correlation with onset and development of HCC and its clinical significance. METHODS: PCR was used to amplify p53 gene exon 5-8 and the immunohistochemistry (SP-p16) was employed to determine the deletion of p16 gene. The difference between the patients with or without liver metastasis was analysed in gene mutation and deletion. RESULTS: Of 33 cases of HLL 17(51.55%), showed the mutation of p53; the mutation rate in metastasis group(n=18) was higher than that in non-metastasis group(n=15). CONCLUSION: There is a correlation between HCC and p53 gene mutation and p16 gene deletion .The mutation rate may have the reference value in diagnosis and prognosis prediction of HCC.